Kyverna Therapeutics Inc.
- Address
- 5980 Horton Street Ste 550
Sponsor Overview
Specializations
Autoimmune Neuromuscular Disorders
Kyverna Therapeutics Inc. focuses on generalized myasthenia gravis, myasthenia gravis, and stiff person syndrome, with clinical interest centered on immune-mediated weakness, neuromuscular transmission disorders, and related autoimmune disease mechanisms.
- Generalized myasthenia gravis
- Myasthenia gravis
- Stiff person syndrome
The sponsor also studies CD19-directed cell therapy approaches in these conditions, reflecting a therapeutic emphasis on refractory neuromuscular autoimmunity.
Inflammatory Kidney Disease
Another major area of interest is lupus nephritis, where the clinical program addresses immune-driven renal inflammation and the management of severe systemic lupus erythematosus-related kidney involvement.
- Lupus nephritis
Research in this area is aligned with immune reconstitution strategies for difficult-to-treat renal autoimmune disease.
Systemic Autoimmune Disease
Kyverna Therapeutics Inc. is active in broader systemic autoimmune disease research, including systemic sclerosis and rheumatoid arthritis, with attention to multi-organ inflammatory involvement and persistent immune dysregulation.
- Systemic sclerosis
- Rheumatoid arthritis
These programs indicate a therapeutic focus on complex autoimmune conditions that affect connective tissue, joints, and internal organs.
Neuroimmunology and Demyelinating Disease
The sponsor also studies primary progressive multiple sclerosis and secondary progressive multiple sclerosis, supporting research in chronic neuroinflammatory and demyelinating disease settings.
- Primary progressive multiple sclerosis
- Secondary progressive multiple sclerosis
This area reflects interest in progressive neurological disability associated with persistent immune-mediated damage in the central nervous system.
Sponsored Trials
| Trial Name | Country | Status |
|---|---|---|
| Evaluation of KYV-101 Anti-CD19 CAR T-Cell Therapy in Refractory Primary and Secondary Progressive Multiple Sclerosis: A Phase 2 Randomized Study |  Austria Belgium Germany Italy | Not Yet Recruiting |
| Long-Term Safety Evaluation of KYV-101 in Patients with Lupus Nephritis, Systemic Sclerosis, Myasthenia Gravis, Rheumatoid Arthritis, or Stiff Person Syndrome | Germany | Recruiting |
| Phase 1/2 Multicenter Study of KYV-101 Anti-CD19 CAR T-Cell Therapy in Refractory Lupus Nephritis | Germany | Not Recruiting |
| Phase 2 Multicenter Study of KYV-101 Anti-CD19 CAR T-Cell Therapy in Refractory Generalized Myasthenia Gravis | Germany | Recruiting |
Data & Insights
This sponsor works with 15 molecules, of which 0 are not being studied by other sponsors.
This sponsor has worked with 15 sites across their trial portfolio.
Therapeutic Focus
- 1.Immune System Diseases4 trials322 other sponsors
- 2.Musculoskeletal Diseases1 trial238 other sponsors
- 3.Nervous System Diseases1 trial449 other sponsors
Partnered Research Centres
15 centres- Address
- Hindenburgdamm 30, Lichterfelde, 12203 Berlin
- Address
- Gudrunstrasse 56, Grumme, 44791 Bochum
- Address
- Ismaninger Strasse 22, Au-Haidhausen, 81675 Munich
- Address
- Waehringer Guertel 18-20, Alsergrund, 1090 Vienna
- Address
- Carl-Neuberg-Strasse 1, Gross Buchholz, 30625 Hanover
- Address
- Via Olgettina 60, 20132 Milan
Want to get in touch with this sponsor?
Send a question and we'll pass it on to Kyverna Therapeutics Inc..
Need a custom report on this sponsor?
Competitive positioning, market entry, partnership opportunities — tell us the question.
Is something out of date?
Tell us what needs correcting and we'll update this profile.